Evolus Inc
Change company Symbol lookup
Select an option...
EOLS Evolus Inc
ADI Analog Devices Inc
BAC Bank of America Corp
CLOV Clover Health Investments Corp
HRL Hormel Foods Corp
DD Dupont De Nemours Inc
PSRU Valiant Eagle Inc
CRM Salesforce.Com Inc
VLYPP Valley National Bancorp
FEMKX Fidelity® Emerging Markets Fund
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

Postmarket

Last Trade
Delayed
$14.17
0.15 (1.07%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$14.02
Day's Change
1.51 (12.07%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
14.50
Day's Low
12.83
Volume
(Light)
Volume:
1,496,648

10-day average volume:
4,533,404
1,496,648

There is no peer information for EOLS.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.